The California STEM Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The California STEM Reporter.

Press releases published on June 2, 2026

Infometry Partners with dbt Labs to Accelerate AI-Ready Data Transformation
SkyWatch Collaborates with Microsoft to Integrate Commercial Satellite Imagery into Planetary Computer Pro
Bigeye Launches Agent Trust Hub to Connect Agent Activity to Trust, Governance and Cost Signals with Runtime Enforcement
EPC Supports AI Infrastructure Built on NVIDIA MGX™ with High-Efficiency 800V-to-12.5V Power Conversion
MoClaw Gives Every User a Cloud Computer — Its AI Agents Now Run Thousands of Tasks a Day, Unattended
INKITT, BACKED BY KHOSLA, NEA AND KLEINER PERKINS, ANNOUNCES INKITT IRONBLOOD: THE FIRST MICRODRAMA PLATFORM FOR ACTION
The MeatStick Introduces MeatStick V Core Set, the Wireless Meat Thermometer Built to Expand
ProLegal Named to Inc.'s Best Workplaces 2026 in the Legal Industry Category
LLŪM Partners with Adaptive to Expand AI-Powered Construction Accounting Services
Smart City Networks Completes Core Network Upgrade at the San Diego Convention Center
Dyad to Bring AMS Modernization Message to Two Major Agency Events
VERZA TV Launches 'The Vertical Tea,' a New Talk Show Covering the Explosive World of Microdramas
Fuel50 Named to Inc.’s 2026 Best Workplaces List
Shopsense AI Launches Shoppable Intelligence Model, Setting a New Standard for Commerce AI
WideField Security Awarded Two U.S. Patents for Foundational Identity Threat Detection and Posture Management Technology
DRAFTWISE RECEIVES G.O.L.T. STAR CERTIFICATION
Viva KRS Launches as a Softer AI Sanctuary for Creativity and Self Reflection
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN® Peanut chez les nourrissons âgés de 6 à 12 mois allergiques à l’arachide
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The California STEM Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.